{"result": "(\"entity\"<|>GSDI<|>EVENT<|>Glycogen Storage Disease Type I (GSDI) is a metabolic disorder characterized by the deficiency of glucose-6-phosphatase, leading to issues in glucose metabolism and storage.)\n##\n(\"entity\"<|>NIGHTTIME ENTERAL NUTRITION<|>EVENT<|>Nighttime enteral nutrition refers to the practice of providing nutritional support through feeding tubes during the night for patients with glycogen storage diseases.)\n##\n(\"entity\"<|>FIBROSIS<|>EVENT<|>Fibrosis is the thickening and scarring of connective tissue, which can occur in the liver of patients with glycogen storage diseases.)\n##\n(\"entity\"<|>MUSCLE COMPLICATIONS<|>EVENT<|>Muscle complications refer to issues related to muscle function and health that can arise in patients with glycogen storage diseases.)\n##\n(\"entity\"<|>GENETIC STUDY<|>EVENT<|>Genetic study involves analyzing genetic mutations to diagnose conditions like glycogen storage diseases, including GSD0.)\n##\n(\"relationship\"<|>GSDI<|>GLYCOGEN SYNTHASE DEFICIENCY<|>Glycogen Synthase Deficiency is related to Glycogen Storage Disease Type I as both are metabolic disorders affecting glycogen metabolism.<|>4)\n##\n(\"relationship\"<|>NIGHTTIME ENTERAL NUTRITION<|>GLYCOGEN SYNTHASE DEFICIENCY<|>Nighttime enteral nutrition is a recommended practice for managing Glycogen Synthase Deficiency to ensure adequate caloric intake.<|>6)\n##\n(\"relationship\"<|>FIBROSIS<|>GLYCOGEN SYNTHASE DEFICIENCY<|>Fibrosis can develop in the liver as a complication of Glycogen Synthase Deficiency due to abnormal glycogen accumulation.<|>5)\n##\n(\"relationship\"<|>MUSCLE COMPLICATIONS<|>GLYCOGEN SYNTHASE DEFICIENCY<|>Muscle complications can arise in patients with Glycogen Synthase Deficiency due to impaired energy metabolism.<|>5)\n##\n(\"relationship\"<|>GENETIC STUDY<|>GLYCOGEN SYNTHASE DEFICIENCY<|>Genetic studies are essential for diagnosing Glycogen Synthase Deficiency by identifying mutations in the GYS2 gene.<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 60-65% (~6 g/kg/día), con\nde duda se realizará biopsia hepática, muscular o de                          reducción progresiva de los suplementos de almidón\nfibroblastos      para   estudio    histológico,     en   donde se            crudo de maíz. Existe incluso algún trabajo en el que se\naprecia la acumulación de glucógeno anómalo ramifi-                           utilizó una dieta Atkins modificada que permitía una\ncado, y en caso de tejido hepático también importante                         ingesta máxima de 10 g/ d de HC (0.4-0.5 g/kg/día)\nfibrosis sin esteatosis.                                                      para inducir la cetosis, con un aporte de proteínas de\n   Se puede realizar diagnóstico prenatal mediante es-                        3-5 g/kg/día y de lípidos de 6-8 g/kg/día. En caso de\ntudio genético de la mutación conocida del caso índice                        suplementación con hidroxibutirato la dosis empleada\nde la familia.                                                                ha sido inicialmente 400 mg/kg/día repartidos cada\n                                                                              3 horas, y aumento progresivo hasta 800 mg/kg/día. Al\n1.3.2.     Objetivos nutricionales                                            menos lo que sí está claro es que en estos pacientes el\n                                                                              aporte del HC no debe suponer más de un 50% del\n   Al igual que en la GSDI, el objetivo es mantener unos                      valor calórico total, ya que una dosis excesiva se ha re-\nniveles de glucemia normales, evitar complicaciones                           lacionado con un peor pronóstico de la miocardiopatía.\ntanto metabólicas como musculares, y mantener un                                 Además, a diferencia de la GSDI, están permitidos no\ncrecimiento y desarrollo adecuados. Las hipoglucemias                         solo la glucosa y sus polímeros, sino otros HC como la\nsuelen ser menos severas, por lo que la demanda de                            fructosa y la galactosa (y por tanto la lactosa y la saca-\naporte de HC es menor, y la mayoría de los pacientes                          rosa), puesto que la gluconeogénesis a partir de los\ndesde el final del primer año de vida mantienen niveles                       mismos sí es eficaz.\nde glucemia normales con un snack nocturno. Se reco-                             También se han observado beneficios con suplemen-\nmienda realizar monitorización de glucemias y cetone-                         tación de MCT en cuanto a mejoría de la hipertriglice-\nmias, sobre todo nocturnas y en ayunas, para controlar                        ridemia, niveles de transaminasas y CK, pero al igual\nla eficacia del tratamiento y evitar sobredosificación y                      que en la GSDI se precisan más estudios para confirmar\nsobrepeso.                                                                    los resultados.\n                                                                                 Los lactantes pueden seguir la lactancia materna\n1.3.3.     Recomendaciones dietéticas                                         normal y, en caso de lactancia artificial no se precisan\n                                                                              fórmulas especiales.\n   Los pacientes deben mantener ingestas cada 3-4 ho-\nras. Tradicionalmente se han dado los mismos consejos                         1.4.    Déficit de glucógeno sintasa hepática\nque en la GSDI, con comidas frecuentes ricas en HC y\nsuplementación con almidón crudo de maíz y/ o nutri-                                  o glucogenosis tipo 0 (GSD0)\nción enteral nocturna, aunque de forma algo más flexi-                        1.4.1.    Fisiopatología y diagnóstico\nble dada la menor severidad de las hipoglucemias y las\ncomplicaciones metabólicas. No obstante, la dieta rica                           La GSD0 constituye un grupo de patologías produci-\nen HC y la suplementación con almidón de maíz está en                         das por la afectación de la isoforma hepática de la glu-\ndiscusión en los últimos años, ya que parece que su                           cógeno sintasa (gen GYS2, 12p12.2), enzima limitante\nexceso puede empeorar la afectación muscular. Por un                          de la glucogenogénesis en este órgano.\nlado, aumenta el acúmulo de glucógeno y dextrina lí-                             Debido a la disminución de la síntesis de glucógeno,\nmite en el músculo, y por otro lado el hiperinsulinismo                       los pacientes presentan en períodos de ayuno hipoglu-\nresultante podría disminuir los sustratos energéticos en                      cemias, cetosis e hipoalaninemia por aumento de la\neste tejido al inhibir la lipólisis, cetogénesis y gluconeo-                  gluconeogénesis. En los períodos postprandiales el ex-\ngénesis. Además, la cetosis activa la succinato deshi-                        ceso de glucosa y sustratos intermedios que no pueden\ndrogenasa mitocondrial en el músculo cardiaco\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>GLYCOGEN SYNTHASE DEFICIENCY<|>EVENT<|>Glycogen Synthase Deficiency (GSD0) is a group of metabolic disorders caused by the deficiency of the liver isoform of glycogen synthase, leading to issues in glycogen synthesis and metabolism.)\n##\n(\"entity\"<|>MCT SUPPLEMENTATION<|>EVENT<|>MCT supplementation refers to the use of medium-chain triglycerides to improve metabolic conditions such as hypertriglyceridemia and liver enzyme levels in patients with glycogen storage diseases.)\n##\n(\"entity\"<|>GENE GYS2<|>ORGANIZATION<|>The GYS2 gene is responsible for encoding the liver isoform of glycogen synthase, which is crucial for glycogen synthesis in the liver.)\n##\n(\"entity\"<|>GLUCOSE<|>ORGANIZATION<|>Glucose is a simple sugar that is a primary energy source for the body and is involved in various metabolic processes, including glycogen synthesis.)\n##\n(\"entity\"<|>LACTOSE<|>ORGANIZATION<|>Lactose is a disaccharide sugar found in milk and dairy products, which can be metabolized into glucose and galactose.)\n##\n(\"entity\"<|>FRUCTOSE<|>ORGANIZATION<|>Fructose is a simple sugar that can be utilized in gluconeogenesis, providing an alternative energy source for patients with glycogen storage diseases.)\n##\n(\"entity\"<|>GALACTOSE<|>ORGANIZATION<|>Galactose is a sugar that, along with glucose, forms lactose and can be converted into glucose for energy.)\n##\n(\"entity\"<|>ALMIDÓN CRUDO DE MAÍZ<|>ORGANIZATION<|>Raw corn starch is a dietary supplement used in managing glycogen storage diseases to provide a source of carbohydrates.)\n##\n(\"entity\"<|>HYPOGLYCEMIA<|>EVENT<|>Hypoglycemia is a condition characterized by abnormally low blood sugar levels, which can occur in patients with glycogen storage diseases.)\n##\n(\"entity\"<|>HYPERTRIGLYCERIDEMIA<|>EVENT<|>Hypertriglyceridemia is a condition of elevated triglycerides in the blood, which can be improved with dietary interventions in glycogen storage disease patients.)\n##\n(\"entity\"<|>NUTRITIONAL GOALS<|>EVENT<|>Nutritional goals for patients with glycogen storage diseases include maintaining normal blood glucose levels and preventing metabolic complications through dietary management.)\n##\n(\"relationship\"<|>GLYCOGEN SYNTHASE DEFICIENCY<|>GENE GYS2<|>Glycogen Synthase Deficiency is caused by mutations in the GYS2 gene, which affects glycogen synthesis in the liver.<|>8)\n##\n(\"relationship\"<|>GLYCOGEN SYNTHASE DEFICIENCY<|>HYPOGLYCEMIA<|>Glycogen Synthase Deficiency can lead to hypoglycemia due to impaired glycogen storage and release during fasting.<|>7)\n##\n(\"relationship\"<|>GLYCOGEN SYNTHASE DEFICIENCY<|>HYPERTRIGLYCERIDEMIA<|>Patients with Glycogen Synthase Deficiency may experience hypertriglyceridemia as a metabolic complication.<|>6)\n##\n(\"relationship\"<|>MCT SUPPLEMENTATION<|>HYPERTRIGLYCERIDEMIA<|>MCT supplementation is used to manage hypertriglyceridemia in patients with glycogen storage diseases.<|>5)\n##\n(\"relationship\"<|>ALMIDÓN CRUDO DE MAÍZ<|>GLYCOGEN SYNTHASE DEFICIENCY<|>Raw corn starch is recommended as a dietary supplement for managing Glycogen Synthase Deficiency.<|>7)\n##\n(\"relationship\"<|>GLUCOSE<|>HYPOGLYCEMIA<|>Glucose intake is crucial for preventing hypoglycemia in patients with glycogen storage diseases.<|>8)\n##\n(\"relationship\"<|>LACTOSE<|>GLUCOSE<|>Lactose is metabolized into glucose, providing an energy source for individuals with glycogen storage diseases.<|>6)\n##\n(\"relationship\"<|>FRUCTOSE<|>GLUCOSE<|>Fructose can be converted into glucose, serving as an alternative energy source for patients with glycogen storage diseases.<|>6)\n##\n(\"relationship\"<|>GALACTOSE<|>GLUCOSE<|>Galactose is converted into glucose, which is essential for energy metabolism in patients with glycogen storage diseases.<|>6)\n<|COMPLETE|>"}]}